Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan
- 841 Downloads
We conducted a 17-year nationwide survey (1999–2015) to elucidate the clinical outcomes of patients with primary myelofibrosis (PMF) in Japan. Questionnaires were sent annually to approximately 500 hematology departments. Newly diagnosed patients with PMF were enrolled in this study, and were followed up annually to collect prognostic information. Approximately 50 patients were enrolled per year, yielding a total of 780 patients with PMF included in this study. The median age at diagnosis was 66 years. At the time of analysis, the median survival duration was 47 months, and the 3-year overall survival rate was 59 %. Infection and disease transformation into acute leukemia were the most frequent causes of death. Of the proposed prognostic models for predicting the outcomes of PMF patients in Japan, the Dynamic International Prognostic Scoring System of PMF plus model was the most feasible. Forty-three patients received allogeneic hematopoietic stem cell transplantation (alloSCT) at a median of 343 days after diagnosis. This treatment significantly prolonged the survival of PMF patients, and the 3-year overall survival rate after first alloSCT was 84 %. A long-term registration study is required for further evaluation of prognosis and the impact of treatments on survival.
KeywordsMyelofibrosis Nationwide survey Long-term outcome
This study was supported by a research grant from the Idiopathic Disorders of Hematopoietic Organs Research Committee of the Ministry of Health, Labor and Welfare of Japan (H23-Nanchi-Ippan-001, H26-Nanchi-Ippan-062, H27-Nanchi-Ippan-017, a Grant-in-Aid for Scientific Research (C) (to K.T., No. 26461424), and a Grant-in-Aid for Scientific Research (S) (to K.A., No. 16H06391). The authors are grateful to their collaborators for their valuable contributions and acknowledge all the institutions that participated in this study and are listed in the supplementary document.
Compliance with ethical standards
Conflict of interest
The authors declare that no conflicts of interest exist.
- 4.Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507–13 (quiz 615. Epub 2014/07/20).CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(24):2995–3001 (Epub 2012/07/18).CrossRefGoogle Scholar
- 10.Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–8 (Epub 2009/12/17).CrossRefPubMedGoogle Scholar
- 11.Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(4):392–7 (Epub 2010/12/15).CrossRefGoogle Scholar
- 23.Tam CS, Kantarjian H, Cortes J, Lynn A, Pierce S, Zhou L, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(33):5587–93 (Epub 2009/09/30).CrossRefGoogle Scholar
- 30.Nangalia J, Green TR. The evolving genomic landscape of myeloproliferative neoplasms. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program. 2014;2014(1):287–96 (Epub 2015/02/20).Google Scholar
- 34.Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100(9):1139–45 (Epub 2015/06/13).Google Scholar